230 related articles for article (PubMed ID: 37133522)
21. Primary mismatch repair deficient IDH-mutant astrocytoma (PMMRDIA) is a distinct type with a poor prognosis.
Suwala AK; Stichel D; Schrimpf D; Kloor M; Wefers AK; Reinhardt A; Maas SLN; Kratz CP; Schweizer L; Hasselblatt M; Snuderl M; Abedalthagafi MSJ; Abdullaev Z; Monoranu CM; Bergmann M; Pekrun A; Freyschlag C; Aronica E; Kramm CM; Hinz F; Sievers P; Korshunov A; Kool M; Pfister SM; Sturm D; Jones DTW; Wick W; Unterberg A; Hartmann C; Dodgshun A; Tabori U; Wesseling P; Sahm F; von Deimling A; Reuss DE
Acta Neuropathol; 2021 Jan; 141(1):85-100. PubMed ID: 33216206
[TBL] [Abstract][Full Text] [Related]
22. Ultra-high-field sodium MRI as biomarker for tumor extent, grade and IDH mutation status in glioma patients.
Regnery S; Behl NGR; Platt T; Weinfurtner N; Windisch P; Deike-Hofmann K; Sahm F; Bendszus M; Debus J; Ladd ME; Schlemmer HP; Rieken S; Adeberg S; Paech D
Neuroimage Clin; 2020; 28():102427. PubMed ID: 33002860
[TBL] [Abstract][Full Text] [Related]
23. Magnetic resonance imaging criteria for prediction of isocitrate dehydrogenase (IDH) mutation status in patients with grade II-III astrocytoma and oligodendroglioma.
Çelik S; Öven BB; Demir MK; Yılmaz EÇ; Kanan D; Özdamarlar U; Emirzeoglu L; Yapıcıer Ö; Kılıç T
Clin Neurol Neurosurg; 2021 Aug; 207():106745. PubMed ID: 34146841
[TBL] [Abstract][Full Text] [Related]
24. The association between
Okita Y; Shofuda T; Kanematsu D; Yoshioka E; Kodama Y; Mano M; Kinoshita M; Nonaka M; Fujinaka T; Kanemura Y
Clin Radiol; 2020 Aug; 75(8):622-628. PubMed ID: 32321646
[TBL] [Abstract][Full Text] [Related]
25. Low expression of Ki-67/MIB-1 labeling index in IDH wild type glioblastoma predicts prolonged survival independently by MGMT methylation status.
Tini P; Yavoroska M; Mazzei MA; Miracco C; Pirtoli L; Tomaciello M; Marampon F; Minniti G
J Neurooncol; 2023 Jun; 163(2):339-344. PubMed ID: 37227648
[TBL] [Abstract][Full Text] [Related]
26. Radio-chemotherapy improves survival in IDH-mutant, 1p/19q non-codeleted secondary high-grade astrocytoma patients.
Juratli TA; Lautenschläger T; Geiger KD; Pinzer T; Krause M; Schackert G; Krex D
J Neurooncol; 2015 Sep; 124(2):197-205. PubMed ID: 26033545
[TBL] [Abstract][Full Text] [Related]
27. Radiomics-based prediction of multiple gene alteration incorporating mutual genetic information in glioblastoma and grade 4 astrocytoma, IDH-mutant.
Sohn B; An C; Kim D; Ahn SS; Han K; Kim SH; Kang SG; Chang JH; Lee SK
J Neurooncol; 2021 Dec; 155(3):267-276. PubMed ID: 34648115
[TBL] [Abstract][Full Text] [Related]
28. Predictive value of MGMT promoter methylation on the survival of TMZ treated
Chai R; Li G; Liu Y; Zhang K; Zhao Z; Wu F; Chang Y; Pang B; Li J; Li Y; Jiang T; Wang Y
Cancer Biol Med; 2021 Feb; 18(1):272-282. PubMed ID: 33628600
[TBL] [Abstract][Full Text] [Related]
29. Relationship between tumor enhancement, edema, IDH1 mutational status, MGMT promoter methylation, and survival in glioblastoma.
Carrillo JA; Lai A; Nghiemphu PL; Kim HJ; Phillips HS; Kharbanda S; Moftakhar P; Lalaezari S; Yong W; Ellingson BM; Cloughesy TF; Pope WB
AJNR Am J Neuroradiol; 2012 Aug; 33(7):1349-55. PubMed ID: 22322613
[TBL] [Abstract][Full Text] [Related]
30. Clinical Neuropathology practice news 2-2014: ATRX, a new candidate biomarker in gliomas.
Haberler C; Wöhrer A
Clin Neuropathol; 2014; 33(2):108-11. PubMed ID: 24559763
[TBL] [Abstract][Full Text] [Related]
31. Monocentric evaluation of Ki-67 labeling index in combination with a modified RPA score as a prognostic factor for survival in IDH-wildtype glioblastoma patients treated with radiochemotherapy.
Dumke R; Dumke C; Eberle F; Nimsky C; Keber U; Engenhart-Cabillic R; Lautenschläger S
Strahlenther Onkol; 2022 Oct; 198(10):892-906. PubMed ID: 35612598
[TBL] [Abstract][Full Text] [Related]
32. Multicenter clinical radiomics-integrated model based on [
Zhang L; Pan H; Liu Z; Gao J; Xu X; Wang L; Wang J; Tang Y; Cao X; Kan Y; Wen Z; Chen J; Huang D; Chen S; Li Y
Eur Radiol; 2023 Feb; 33(2):872-883. PubMed ID: 35984514
[TBL] [Abstract][Full Text] [Related]
33. Diffusion- and perfusion-weighted MRI radiomics model may predict isocitrate dehydrogenase (IDH) mutation and tumor aggressiveness in diffuse lower grade glioma.
Kim M; Jung SY; Park JE; Jo Y; Park SY; Nam SJ; Kim JH; Kim HS
Eur Radiol; 2020 Apr; 30(4):2142-2151. PubMed ID: 31828414
[TBL] [Abstract][Full Text] [Related]
34. Use of telomerase promoter mutations to mark specific molecular subsets with reciprocal clinical behavior in IDH mutant and IDH wild-type diffuse gliomas.
Akyerli CB; Yüksel Ş; Can Ö; Erson-Omay EZ; Oktay Y; Coşgun E; Ülgen E; Erdemgil Y; Sav A; von Deimling A; Günel M; Yakıcıer MC; Pamir MN; Özduman K
J Neurosurg; 2018 Apr; 128(4):1102-1114. PubMed ID: 28621624
[TBL] [Abstract][Full Text] [Related]
35. Comparison of Radiomics Analyses Based on Different Magnetic Resonance Imaging Sequences in Grading and Molecular Genomic Typing of Glioma.
Huang WY; Wen LH; Wu G; Hu MZ; Zhang CC; Chen F; Zhao JN
J Comput Assist Tomogr; 2021 Jan-Feb 01; 45(1):110-120. PubMed ID: 33475317
[TBL] [Abstract][Full Text] [Related]
36. Low MGMT digital expression is associated with a better outcome of IDH1 wildtype glioblastomas treated with temozolomide.
Gomes I; Moreno DA; Dos Reis MB; da Silva LS; Leal LF; Gonçalves GM; Pereira CA; Oliveira MA; de Medeiros Matsushita M; Reis RM
J Neurooncol; 2021 Jan; 151(2):135-144. PubMed ID: 33400009
[TBL] [Abstract][Full Text] [Related]
37. Noninvasively evaluating the grade and IDH mutation status of gliomas by using mono-exponential, bi-exponential diffusion-weighted imaging and three-dimensional pseudo-continuous arterial spin labeling.
Guo D; Jiang B
Eur J Radiol; 2023 Mar; 160():110721. PubMed ID: 36738600
[TBL] [Abstract][Full Text] [Related]
38. MRI features predict tumor grade in isocitrate dehydrogenase (IDH)-mutant astrocytoma and oligodendroglioma.
Joyner DA; Garrett J; Batchala PP; Rama B; Ravicz JR; Patrie JT; Lopes MB; Fadul CE; Schiff D; Jain R; Patel SH
Neuroradiology; 2023 Jan; 65(1):121-129. PubMed ID: 35953567
[TBL] [Abstract][Full Text] [Related]
39. Radiogenomics correlation between MR imaging features and major genetic profiles in glioblastoma.
Hong EK; Choi SH; Shin DJ; Jo SW; Yoo RE; Kang KM; Yun TJ; Kim JH; Sohn CH; Park SH; Won JK; Kim TM; Park CK; Kim IH; Lee ST
Eur Radiol; 2018 Oct; 28(10):4350-4361. PubMed ID: 29721688
[TBL] [Abstract][Full Text] [Related]
40. ATRX loss in adult supratentorial diffuse astrocytomas correlates with p53 over expression and IDH1 mutation and predicts better outcome in p53 accumulated patients.
Shao LW; Pan Y; Qi XL; Li YX; Ma XL; Yi WN; Zhang J; Zhong YF; Chang Q
Histol Histopathol; 2016 Jan; 31(1):103-14. PubMed ID: 26395639
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]